Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.59 |
| ▸ | PPARA | Q07869 | 8/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722270 | 1.00 | PPARG (0.59) | PPARGPPARACYP4F2CYP4A11GHSR | |
| SCHEMBL2717563 | 0.91 | PPARG (0.63) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2717561 | 0.91 | PPARG (0.63) | PPARGPPARACYP4F2CYP4A11MEN1 | |
| SCHEMBL2719917 | 0.90 | PPARG (0.52) | PPARGPPARAGHSRNPC1RAB9A | |
| SCHEMBL2978823 | 0.90 | PPARG (0.52) | PPARGPPARAGHSRNPC1RAB9A | |
| SCHEMBL2719920 | 0.90 | PPARG (0.52) | PPARGPPARAGHSRNPC1RAB9A | |
| SCHEMBL6600231 | 0.87 | PPARG (0.67) | PPARGPPARACYP4F2CYP4A11NPC1 | |
| SCHEMBL6600223 | 0.87 | PPARG (0.67) | PPARGPPARACYP4F2CYP4A11NPC1 | |
| SCHEMBL14143467 | 0.83 | PPARG (0.70) | PPARGPPARACYP4F2CYP4A11NPC1 | |
| SCHEMBL2718448 | 0.83 | PPARG (0.75) | PPARGPPARACYP4F2CYP4A11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647546-B1 | NOVEL HETEROARYL DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | DANIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-7425642-B2 | Heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20060194857-A1 | Novel heteroaryl derivative | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1647546-A1 | NOVEL HETEROARYL DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194857-A1 | Novel heteroaryl derivative | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885CYP4F2 97/4885 |
| US-20080306275-A1 | NOVEL HETEROARYL DERIVATIVE | NR0B1, UGT1A10, NR0B2 | PPARG 282/4885PPARA 411/4885CYP4F2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.